COVID-19 Implications for Pharmaceutical Litigation
Darius Lakdawalla of the University of Southern California discusses the economics of pharmaceutical markets and the impacts of COVID-19 from the manufacturer perspective.
2020 IAM Guide to Leading Patent Professionals
Intellectual Asset Management (IAM) names Henry Grabowski of Duke University and Matthew Lynde of Cornerstone Research in its annual list of leading expert witnesses on patent issues in the United…
In re Intuniv Antitrust Litigation
The judge denied class certification in this pharmaceutical pay-for-delay case brought by a class of indirect purchasers.
Cigna’s Acquisition of Express Scripts
The parties completed a $67 billion merger after receiving clearance from the U.S. Department of Justice and state departments of insurance.
Hsu et al. v. Puma Biotechnology Inc. et al.
Positive jury verdict in rare securities class action trial.
Competition Law and Economics in Pharmaceutical Markets
Cornerstone Research hosted expert forums in London and Brussels to examine recent competition cases in Europe.
Product Hopping
Pharmaceutical manufacturers have been accused of engaging in product hopping by introducing modified versions of branded drugs nearing patent expiry while simultaneously withdrawing the older drugs to hinder generic substitution.
Sampling in FCA Litigation
Clients draw on Cornerstone Research's statistical expertise to evaluate sampling analyses performed by opposing parties to prove liability and damages in False Claims Act litigation.
Joint Development Marketing Dispute
Cornerstone Research worked with a life sciences competition expert in a dispute between two pharmaceutical companies that jointly developed a drug.
Allergan Takeover Bid
Cornerstone Research worked with two experts who testified on Rule 14e-3 allegations that a hedge fund violated federal securities law on disclosures in cash tender offers.
Alleged Theft of Trade Secrets for a Drug in Development
Professor Sean Nicholson and Cornerstone Research analyzed the loss in value of a drug in development due to the advantage that the manufacturer of a competing drug in development obtained…
Breach of Contract for a Branded Drug
Cornerstone Research and an affiliated expert analyzed the impact on a branded drug's value when a pharmaceutical company interrupted the supply and promotion of the drug.
How can we help you?
If you are looking for a publication not on our website, contact us.